Clinicopathological and molecular differences between stage IV screen-detected and interval colorectal cancers in the Flemish screening program

IntroductionInterval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC.MethodsLogistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location.ResultsA total of... Mehr ...

Verfasser: Isabelle Neefs
Thuy Ngan Tran
Allegra Ferrari
Sharon Janssens
Koen Van Herck
Ken Op de Beeck
Guy Van Camp
Marc Peeters
Erik Fransen
Sarah Hoeck
Guido Van Hal
Dokumenttyp: Artikel
Erscheinungsdatum: 2024
Reihe/Periodikum: Frontiers in Oncology, Vol 14 (2024)
Verlag/Hrsg.: Frontiers Media S.A.
Schlagwörter: colorectal cancer / clinicopathological differences / interval cancer / molecular alterations / screening / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29060462
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3389/fonc.2024.1409196

IntroductionInterval cancer (IC) is an important quality indicator in colorectal cancer (CRC) screening. Previously, we found that fecal immunochemical test (FIT) ICs are more common in women, older age, right-sided tumors, and advanced stage. Here, we extended our existing stage IV patient cohort with clinicopathological and molecular characteristics, to identify factors associated with FIT-IC.MethodsLogistic regression models were fit to identify variables associated with the odds of having a stage IV FIT-IC. Multivariate models were corrected for gender, age, and location.ResultsA total of 292 screen-detected (SD) CRCs and 215 FIT-IC CRCs were included. FIT-IC CRC had 5 fold higher odds to be a neuroendocrine (NET) tumor and 2.5 fold higher odds to have lymphovascular invasion. Interestingly, some variables lost significance upon accounting for location. Thus, tumor location is a critical covariate that should always be included when evaluating factors related to FIT-IC.ConclusionsWe identified NETs and lymphovascular invasion as factors associated with increased odds of having a stage IV FIT-IC. Moreover, we highlight the importance of tumor location as a covariate in evaluating FIT-IC related factors. More research across all stages is needed to clarify how these insights might help to optimize the Flemish CRC screening program.